Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB849 +/- Pembrolizumab in Advanced Solid Tumors
NCT05761223Phase 2Recruiting
- Sponsor
- 1ST Biotherapeutics
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FB849 in solid tumor (advanced stage), sponsored by 1ST Biotherapeutics. Started Dec 2023; status: recruiting.
02
Drugs
FB849
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05761223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761223.